When was Neuronetics founded?

Neuronetics was founded in 2001 and raised its 1st funding round within a year of its incorporation.

Where is Neuronetics located?

Neuronetics is headquartered in Malvern, United States. It is registered at Malvern, Pennsylvania.

How many employees does Neuronetics have?

As of Mar 31, 2026, the latest employee count at Neuronetics is 216.

Is Neuronetics a funded company?

Neuronetics is a funded company, having raised a total of $178M across 8 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Aug 22, 2001.

When was the latest funding round of Neuronetics?

Neuronetics' latest funding was a $***** Series G round on Jun 06, 2017, with participation from 12 investors.

What is the annual revenue of Neuronetics?

Annual revenue of Neuronetics is $149M as on Dec 31, 2025.

Where does Neuronetics rank among its competitors?

Neuronetics ranks 4th amongst 17 active competitors, of which 5 are funded. It stands 1st in terms of total funding among its competitors. The most recent competitor to raise funding was NeuroQore, which secured $1.51M in Jul, 2025.

Who are the top competitors of Neuronetics?

Neuronetics' top competitors include NeuroStar, Flow Neuroscience and Magnus Medical. Among them, NeuroQore secured the most recent funding round in July, 2025.

Neuronetics - 2026 Company Profile, Funding, Competitors & Financials

Neuronetics is a series G company based in Malvern (United States), founded in 2001. It operates as a Transforming neurohealth with innovative, non-drug TMS therapy for mental health. Neuronetics has raised $178M in funding from Polaris Partners and Pfizer Venture Investments. The company has 17 active competitors, including 5 funded and 3 that have exited. Its top competitors include companies like NeuroStar, Flow Neuroscience and Magnus Medical.

Company Details

Transforming neurohealth with innovative, non-drug TMS therapy for mental health. The company is dedicated to improving the lives of individuals suffering from psychiatric disorders by offering patient-centric medical devices. They specialize in transcranial magnetic stimulation (TMS) treatment, providing a non-drug, non-invasive alternative for those with depression and OCD. Committed to practice success, they offer ongoing support and strive to expand their capabilities to cover additional indications. Their approach focuses on compassion, innovation, and growth, aiming to provide a safe, effective, and durable treatment option. They are committed to compliance and ethical practices, ensuring the highest quality of care for both patients and healthcare providers.

Website: neuronetics.com
Social
Registered Address: Malvern, Pennsylvania

Key Metrics

Founded Year

2001

Location

Malvern, United States

Stage

Series G

Total Funding

$178M in 8 rounds

Latest Funding Round

Series G, Jun 06, 2017, $*****

Investors

Polaris Partners & 17 more

Ranked

4^th among 17 active competitors

Annual Revenue

$149M as on Dec 31, 2025

Employee Count

216 as on Mar 31, 2026

Similar Companies

NeuroStar & 15 more

View Neuronetics' full profile

Neuronetics is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Neuronetics, Inc. CIN: 331051425 , United States, Active		$149M (As on Dec 31, 2025)	312 (As on Dec 31, 2023)	-

Neuronetics has raised a total funding of $178M over 8 rounds. Its first funding round was on Aug 22, 2001. Its latest funding round was a Series G round on Jun 06, 2017 for $*****. 12 investors participated in its latest round. Neuronetics has 18 institutional investors.

Here is the list of recent funding rounds of Neuronetics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 06, 2017	2816444	Series G	8063546	2691289	5544260	9445608
Apr 27, 2015	2238554	Series F	4117733	6153934	1169481	General Electric
May 16, 2011	3889561	Series E	9551451	7702515	Polaris Partners & 1 more	New Leaf Venture Partners & 5 more

Access funding benchmarks and valuations. Sign up today!

View details of Neuronetics's funding rounds and investors

Neuronetics' employee count trend

Neuronetics has 216 employees as of Mar 26. Here is Neuronetics's employee count trend over the years:

Uncover Neuronetics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Neuronetics include NeuroStar, Flow Neuroscience and Magnus Medical. Here is the list of Top 10 competitors of Neuronetics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	NeuroStar 2003, Malvern (United States), Public	Provider of a non-drug non-invasive therapeutic devices for neurorehabilitation	$119M	Ascension Ventures, Quaker Partners Management ... & 14 others	70/100
2nd	Flow Neuroscience 2016, Malmo (Sweden), Series A	Provider of a wearable device for stress and anxiety management	$11.9M	Khosla Ventures, HAX & 6 others	61/100
3rd	Magnus Medical 2017, Burlingame (United States), Series B	Provider of non invasive neuromodulation system for depression treatment	$89M	Red Tree Venture Capital, JAZZ Venture Partners ... & 1 others	59/100
4th	Neuronetics 2001, Malvern (United States), Series G	Transforming neurohealth with innovative, non-drug TMS therapy for mental health	$178M	Quaker Partners Management, Industry Ventures ... & 16 others	60/100
5th	Magstim 1990, Whitland (United Kingdom), Acquired	Developer of EEG, TMS, and tDCS neurotechnology solutions	$32.1M	Finance Wales, Telegraph Hill Partners & 1 others	52/100
6th	Soterix Medical 2008, New York City (United States), Funding Raised	Neuromodulation and brain stimulation technology for neuropsychiatric and neurological disorders	-	NINDS, HHS	41/100
7th	Tonic 1991, Farum (Denmark), Unfunded	Manufacturer of transcranial magnetic stimulation (TMS) systems for research and treatment	-	-	39/100
8th	Brainsway 2003, Jerusalem (Israel), Public	Develoepr of noninvasive neurostimulation treatments for mental health disorders	-	Shavit Capital, Fnx & 3 others	36/100
9th	Neuroprex 2012, Santa Clara (United States), Seed	Developer of a wearable device to modulate tissue for neurological diseases	$50K	National Science Foundation, EIC Fund & 1 others	32/100
10th	NeuroQore 2012, Ottawa (Canada), Series A	Develops a monophasic repetitive transcranial magnetic stimulation (rTMS) system	$1.76M	IndieBio, Ontario Brain Institute & 1 others	27/100